Acute demyelinating neuropathy associated with rituximab treatment in a patient with relapsing nephrotic syndrome

Cravedi P. Rituximab in membranous nephropathy: not all studies are created equal. Nephron. 2017;135:46–50. Iancu Ferfoglia R, Guimarães-Costa R, Viala K, et al. Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study. J Peripher Nerv Syst. 2016;21:10–4. Stork AC, Notermans NC, Vrancken AF, Cornblath DR, van der Pol WL. Rapid worsening of IgM anti-MAG demyelinating polyneuropathy during rituximab treatment. J Peripher Nerv Syst. 2013;18:189–91. Terenghi F, Ardolino G, Nobile-Orazio E. Guillain–Barré syndrome after combined CHOP and rituximab therapy in non-Hodgkin lymphoma. J Peripher Nerv Syst. 2007;12:142–3. Weiss MD, Becker P. Paradoxical worsening of anti-myelin associated glycoprotein polyneuropathy following rituximab. Muscle Nerve. 2014;49:457–8.